News and Trends 6 Jan 2023 Transgene approved for IV oncolytic virus trial Transgene has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I clinical trial of TG6050. TG6050 is a novel oncolytic virus (OV) that will be administered intravenously in patients with advanced non-small cell lung cancer (NSCLC). Transgene is […] January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals This week, we have two guests. We have conversations with Newron CEO, Stefan Weber, and Mainz Biomed CEO, Guido Bächler. Mainz Biomed year-end corporate review Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its corporate summary for the fiscal year ended December 31, 2022. The company launched […] January 6, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 Ensoma acquiring Twelve Bio Arix Bioscience, a global venture capital company focused on investing in breakthrough biotechnology companies, announced that portfolio company Twelve Bio will be acquired by Ensoma in connection with an $85 million financing of Ensoma which Arix co-led, investing $9 million. Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. […] January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 C2i Genomics extends AstraZeneca cancer deal C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring. C2i genomics has completed AstraZeneca’s BeyondBio Innovation Hub’s […] January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […] January 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 5 Jan 2023 Navignostics maps tumor proteomes to improve precision oncology New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most. The Swiss firm Navignostics is making spatial maps of the tumor’s proteome to identify the right treatment for the patient and boost precision oncology approaches. A wide range of technologies is being deployed in the […] January 5, 2023 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Cancer Research UK and Turbine to partner on program Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, has announced that it is partnering with Turbine AI, a tech-enabled biotech leveraging its proprietary Simulated Cell platform to solve complex diseases. The partnership will utilize Turbine AI’s platform to identify target patient populations […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Hummingbird Bioscience and Synaffix to develop ADC program Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix is a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ADCs. Hummingbird Bioscience is a data-driven precision biotherapeutics company using […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2023 Actimed Therapeutics raises £10M for cancer cachexia treatment Actimed Therapeutics Ltd has completed its second and final £5 million ($6 million) tranche of seed financing. The round was closed with an investment by Indian pharmaceutical company, Mankind Pharma, marking Mankind’s first overseas investment of this type. Actimed Therapeutics is a U.K. based clinical stage specialty pharmaceutical company focused on bringing innovation to the […] January 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Janssen looks for talquetamab marketing approval The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody targeting both GPRC5D, a novel drug […] January 3, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Legend Biotech new drug application approved in China Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted its new drug application (NDA) for ciltacabtagene autoleucel (cilta-cel). This submission is based on data from the confirmatory phase 2 clinical study CARTIFAN-1, conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or […] January 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […] January 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email